-continued

Leu Glu Val Leu Phe Gln Gly Pro
1 5

<210> SEQ ID NO 165
<211> LENGTH: 92
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 165

cattttcaat taagatgcag ttacttcgct gtttttcaat attttctgtt attgctagcg 60

ttttagcaat ggcccaggtg cagctgcagg ag 92

<210> SEQ ID NO 166
<211> LENGTH: 81
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 166

ccaccagatc caccaccacc caaggtcttc ttcggagata agcttttgtt cggatcctga 60

ggagacggtg acctgggtcc c 81

What is claimed is:

1. A variable domain of a heavy chain-only antibody (VHH antibody) comprising:

an amino acid sequence that consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementary determining regions (CDR1 to CDR3, respectively) according to the formula: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4;

wherein CDR1 is the amino acid sequence of SEQ ID NO:31 or an amino acid sequence having at least 85% identity with SEQ ID NO:31;

wherein CDR2 is the amino acid sequence of SEQ ID NO:53 or an amino acid sequence having at least 85% identity with SEQ ID NO:53; and

wherein CDR3 is the amino acid sequence of SEQ ID NO:75 or an amino acid sequence having at least 85% identity with SEQ ID NO:75.

2. The VHH antibody of claim **1**, wherein the VHH antibody comprises an amino acid sequence that has at least 80% identity with the amino acid sequence of SEQ ID NO: 1.

3. The VHH antibody of claim **1**, wherein the VHH antibody comprises an amino acid sequence that has at least 85% identity with the amino acid sequence of SEQ ID NO: 1.

4. The VHH antibody of claim **1**, wherein the VHH antibody comprises an amino acid sequence that has at least 90% identity with the amino acid sequence of SEQ ID NO: 1.

5. The VHH antibody of claim **1**, wherein the VHH antibody comprises an amino acid sequence that has at least 95% identity with the amino acid sequence of SEQ ID NO: 1.

6. The VHH antibody of claim **1**, wherein the VHH antibody comprises an amino acid sequence that has at least 99% identity with the amino acid sequence of SEQ ID NO: 1.

7. The VHH antibody of claim **1**, wherein CDR1 is the amino acid sequence of SEQ ID NO:31 and CDR2 is the amino acid sequence of SEQ ID NO:53.

8. The VHH antibody of claim **1**, wherein CDR1 is the amino acid sequence of SEQ ID NO:31 and CDR3 is the amino acid sequence of SEQ ID NO:75.

9. The VHH antibody of claim **1**, wherein CDR2 is the amino acid sequence of SEQ ID NO:53 and CDR3 is the amino acid sequence of SEQ ID NO:75.

10. The VHH antibody of claim **1**, wherein the framework regions are the framework regions of SEQ ID NO: 1.

11. The VHH antibody of claim **10**, wherein the VHH antibody has binding activity for a muscarinic receptor M2.

12. The VHH antibody of claim **6**, wherein the framework regions are the framework regions of SEQ ID NO: 1.

13. The VHH antibody of claim **12**, wherein the VHH antibody has binding activity for a muscarinic receptor M2

14. The VHH antibody of claim **7**, wherein the framework regions are the framework regions of SEQ ID NO: 1.

15. The VHH antibody of claim **14**, wherein the VHH antibody has binding activity for a muscarinic receptor M2

16. The VHH antibody of claim **5**, wherein the framework regions are the framework regions of SEQ ID NO: 1.

17. The VHH antibody of claim **16**, wherein the VHH antibody has binding activity for a muscarinic receptor M2

18. The VHH antibody of claim **4**, wherein the framework regions are the framework regions of SEQ ID NO: 1.

19. A method of compound screening and/or drug discovery, the method comprising: